Open-Label, Safety Study Evaluating the Use of Dexmedetomidine in Pediatric Subjects Undergoing Procedure-Type Sedation
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety of dexmedetomidine in a pediatric
population requiring non-intubated, spontaneous breathing, moderate to deep sedation (NI-MDS)
for elective diagnostic or therapeutic procedures, expected to take more than 30 minutes.
Phase:
Phase 4
Details
Lead Sponsor:
Hospira, Inc. Hospira, now a wholly owned subsidiary of Pfizer